淡江大學機構典藏:Item 987654321/78544
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 62813/95882 (66%)
Visitors : 3995720      Online Users : 611
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/78544


    Title: Clozapine Protects Bone Mineral Density in Female Patients with Schizophrenia
    Authors: Lin, Chieh-hsin;Huang, Kuo-hao;Chang, Yue-cune;Huang, Yi-chen;Hsu, Wan-chih;Lin, Chun-yuan;Chou, Frank Huang-chih;Tsai, Guochuan E.;Lane, Hsien-yuan
    Contributors: 淡江大學數學學系
    Keywords: Bone mineral density;clozapine;osteoporosis;prolactin;schizophrenia
    Date: 2012-08-01
    Issue Date: 2012-10-11 19:34:38 (UTC+8)
    Publisher: Cambridge: Cambridge University Press
    Abstract: Decreased bone mineral density (BMD) is common in patients with schizophrenia; however, the pathogenesis is unclear. Different classes of antipsychotic agents may affect BMD. This study systemically examined the effects of clozapine vs. other antipsychotics, and several hormonal and metabolic factors that may contribute to BMD in female patients with schizophrenia, who are more vulnerable than males. Forty-eight women with schizophrenia, treated with long-term antipsychotics of the prototype prolactin-sparing (PS) antipsychotic agent clozapine vs. prolactin-raising (PR) antipsychotics were enrolled. They were matched for demographic and clinical characteristics. Various factors, including blood levels of prolactin and sex hormones, psychopathological symptoms, global assessment of functioning, physical activity, and menopausal status, were determined to explore their contribution to low BMD (LBMD), defined as a dual-energy X-ray absorptiometer (DEXA) T score ＜ -1. Overall, women receiving clozapine have better bone density than women receiving PR antipsychotics. Compared to PR antipsychotics, PS clozapine therapy is a protective factor (odds ratio 28.2, 95% confidence interval 2.37-336.10, p=0.008) for LBMD. Predictors for higher bone density in the clozapine group included higher clozapine dose (p＜0.001), younger age (p＜0.001), and higher thyroid-stimulating hormone level (p＜0.001); in the PR group, higher body mass index (p=0.003) and lower alkaline phosphatase level (p=0.007) were associated with LBMD. This study suggests that clozapine treatment is beneficial for BMD compared to PR antipsychotic treatment in women with chronic schizophrenia, and clozapine's bone-density protecting effect is dose-related.
    Relation: The International Journal of Neuropsychopharmacology 15(7), pp.897-906
    DOI: 10.1017/S1461145711001507
    Appears in Collections:[Graduate Institute & Department of Mathematics] Journal Article

    Files in This Item:

    File Description SizeFormat
    109. International Journal of Neuropsychopharmacology(clo BMD IJNP online2011).pdf3937KbAdobe PDF444View/Open
    index.html0KbHTML144View/Open

    All items in 機構典藏 are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - Feedback